Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

FBIOX Fidelity® Select Biotechnology

  • Fund
  • FBIOX
  • Price as of: Nov 17, 2017
  • $214.70
  • + $0.14
  • + 0.07%
  • Category
  • Health & Biotech Equities

FBIOX - Profile

Vitals

  • YTD Return 23.4%
  • 3 Yr Annualized Return 4.6%
  • 5 Yr Annualized Return 20.3%
  • Net Assets $9.18 B
  • Holdings in Top 10 40.0%

52 WEEK LOW AND HIGH

$214.70
$174.05
$236.41

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.75%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 28.00%

TRADING FEES

  • Max Redemption Fee 0.75%

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

$2,500

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 23.4%
  • 3 Yr Annualized Total Return 4.6%
  • 5 Yr Annualized Total Return 20.3%
  • Capital Gain Distribution Frequency Semi-Annually
  • Net Income Ratio -0.43%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Fidelity® Select Biotechnology Portfolio
  • Fund Family Name Fidelity Investments
  • Inception Date Dec 16, 1985
  • Shares Outstanding N/A
  • Share Class No Load
  • Currency USD
  • Domiciled Country United States
  • Manager Rajiv Kaul

Fund Description

Fidelity Select Biotechnology Portfolio (FBIOX) is an actively managed mutual fund managed by Fidelity. The fund is focused primarily on the biotechnology industry and its operations. It is compiled primarily of U.S. common stocks in the healthcare industry with some exposure to the services industries. In general, this fund tends to have 80% of its holdings in stocks that are focused in research, development, manufacturing, and distribution of biotechnological products, services, processes and companies. The fund has been managed by Rajiv Kaul since 2005 and was launched on December 16, 1985.

The fund is very focused on capital appreciation but carries a higher amount of risk since it is sector-focused and has little diversification. The fund holds additional risk since the companies are affected by patent considerations, high competition, technological changes and government regulations. Despite its risk, the biotechnology industry is well known for its high risk and reward and may be ideal for aggressive investors seeking growth and high returns in their portfolio. In addition, sector based mutual funds such as the Fidelity Select Biotechnology Portfolio may be a good alternative for investors seeking exposure to the biotechnology industry without buying specific stocks.

Holdings in this fund are generally large cap growth stocks. The fund’s holdings are determined by analyzing drug pipelines, the size of market opportunities and the valuations. Typically, this fund holds long term growth stocks, companies with attractive drug pipelines, turnaround companies, breakthrough companies and startups.

The fund’s holdings are chosen by using various factors including financial conditions, industry position, and current economic and market conditions. This fund aims to outperform the benchmark through its active management. The fund pays dividends and capital gains every year in April and December.

This fund requires a minimum initial investment of $2,500 for both regular and IRA accounts.

FBIOX - Performance

Return Ranking - Trailing

Period FBIOX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 23.4% -14.9% 36.8% 24.11% 2
1 Yr 30.7% -14.8% 43.9% 11.71% 1
3 Yr 4.6% * -7.5% 18.5% 73.15% 4
5 Yr 20.3% * 9.3% 22.0% 3.88% 1
10 Yr 14.7% * 6.1% 17.5% 9.71% 1

* Annualized


Return Ranking - Calendar

Period FBIOX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -26.2% -29.8% 2.6% 96.36% 5
2015 6.6% -20.4% 14.5% 8.18% 1
2014 21.8% -5.8% 33.7% 24.55% 2
2013 65.2% -2.6% 65.2% 0.92% 1
2012 27.7% -5.3% 36.5% 8.74% 1

Total Return Ranking - Trailing

Period FBIOX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 23.4% -14.9% 36.8% 24.32% 2
1 Yr 30.7% -18.3% 43.9% 10.91% 1
3 Yr 4.6% * -14.2% 18.5% 70.37% 4
5 Yr 20.3% * 9.1% 22.0% 3.88% 1
10 Yr 14.7% * 6.1% 17.2% 6.80% 1

* Annualized


Total Return Ranking - Calendar

Period FBIOX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -24.3% -25.1% 6.3% 96.33% 5
2015 15.3% -16.6% 39.1% 5.50% 1
2014 46.6% -5.8% 100.0% 10.09% 1
2013 113.0% -5.1% 398.7% 11.11% 1
2012 90.6% -2.6% 475.8% 10.00% 1

NAV & Total Return History

FBIOX - Holdings

Filings data as of: Sep 30, 2017

Concentration Analysis

FBIOX Category Low Category High FBIOX % Rank Quintile
Net Assets 9.18 B 18.6 M 47 B 2.68% 1
Number of Holdings 233 31 361 4.46% 1
Net Assets in Top 10 4 B 11 M 20.2 B 1.79% 1
Weighting of Top 10 40.0% 19.8% 71.2% 27.68% 3

Top 10 Holdings

  1. Vertex Pharmaceuticals Inc 3.77%
  2. Celgene Corp 6.21%
  3. Regeneron Pharmaceuticals Inc 4.57%
  4. Alexion Pharmaceuticals Inc 4.46%
  5. Biomarin Pharmaceutical Inc 1.72%
  6. Biogen Inc 3.86%
  7. Incyte Corp 1.82%
  8. Amgen Inc 9.82%
  9. Alnylam Pharmaceuticals Inc 2.13%
  10. Gilead Sciences Inc 1.62%

Asset Allocation

Weighting Category Low Category High FBIOX % Rank Quintile
Stocks
97.54% 91.83% 99.98% 18.75% 2
Preferred Stocks
1.99% 0.00% 4.16% 6.25% 1
Cash
0.48% -0.04% 5.66% 31.25% 4
Other
0.00% -5.64% 5.15% 18.75% 5
Convertible Bonds
0.00% 0.00% 0.46% 2.68% 5
Bonds
0.00% 0.00% 4.69% 7.14% 5

Stock Sector Breakdown

Weighting Category Low Category High FBIOX % Rank Quintile
Healthcare
96.76% 11.15% 99.98% 8.93% 1
Utilities
0.00% 0.00% 0.95% 1.79% 5
Technology
0.00% 0.00% 65.49% 33.04% 5
Real Estate
0.00% 0.00% 1.52% 1.79% 5
Industrials
0.00% 0.00% 8.26% 8.04% 5
Financial Services
0.00% 0.00% 2.90% 6.25% 5
Energy
0.00% 0.00% 0.09% 1.79% 5
Communication Services
0.00% 0.00% 0.00% 0.89% 5
Consumer Defense
0.00% 0.00% 1.65% 14.29% 5
Consumer Cyclical
0.00% 0.00% 7.41% 7.14% 5
Basic Materials
0.00% 0.00% 2.25% 6.25% 5

Stock Geographic Breakdown

Weighting Category Low Category High FBIOX % Rank Quintile
US
93.94% 60.72% 99.98% 11.61% 2
Non US
3.60% 0.00% 34.72% 33.93% 5

FBIOX - Expenses

Operational Fees

FBIOX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.75% 0.10% 4.31% 64.29% 1
Management Fee 0.55% 0.09% 1.25% 14.29% 1
12b-1 Fee N/A 0.00% 1.00% N/A N/A
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

FBIOX Fees (% of AUM) Category Low Category High FBIOX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

FBIOX Fees (% of AUM) Category Low Category High FBIOX Rank Quintile
Max Redemption Fee 0.75% 0.75% 2.00% 6.82% 2

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBIOX Fees (% of AUM) Category Low Category High FBIOX Rank Quintile
Turnover 28.00% 0.00% 699.00% 20.54% 2

FBIOX - Distributions

Dividend Yield Analysis

FBIOX Category Low Category High FBIOX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

FBIOX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

FBIOX Category Low Category High FBIOX % Rank Quintile
Net Income Ratio -0.43% -2.22% 1.46% 41.07% 3

Capital Gain Distribution Analysis

FBIOX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Semi-Annually Annually Semi-Annually Annually

FBIOX - Managers

Rajiv Kaul

Manager

Start Date

Oct 12, 2005

Tenure

12.06

Tenure Rank

12.6%

Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. Prior to Fidelity, Kaul worked at Mckinsey & Company. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.


Tenure Analysis

Category Low

0.3

Category High

20.1

Category Average

9.06

Category Mode

0.7